Medtronic announces new results from CoreValve ADVANCE Study

Medtronic, Inc. (NYSE: MDT) today announced new results from the Medtronic CoreValve ADVANCE Study, which found that women and men benefitted similarly from the Medtronic CoreValve® System. The study, presented at EuroPCR 2012, evaluated patients who were at high-risk for surgical aortic valve replacement. The Medtronic CoreValve System is currently limited to investigational use in the United States.    

The gender analysis, a secondary-endpoint evaluation in the real-world CoreValve ADVANCE Study, found that survival rates were nearly identical between genders, with no statistical differences in 30-day and 6-month all-cause mortality, cardiovascular mortality or the 30-day MACCE endpoint (Major Adverse Cardiac & Cerebrovascular Events, a composite of all-cause mortality, myocardial infarction, emergent cardiac surgery or percutaneous re-intervention, and stroke).

Overall, patients experienced low 30-day stroke rates (2.9 percent overall), with the combined stroke rates of major and minor strokes being very low (major 1.2 percent, and minor 1.7 percent). However, female patients experienced a statistically higher rate of strokes (4.4 percent vs. 1.4 percent; p-value <0.01), major vascular complications (14.1 percent vs. 7.1 percent; p-value <0.01) and major bleeding (5.0 percent vs. 3.1 percent; p-value <0.01). For minor stroke between genders, and for major strokes between genders, differences were not significant, though there was a trend for women to have more minor strokes than men.

"This study is an important contribution to the growing base of research on TAVI, and sheds light on the unique needs for managing severe aortic stenosis in women," said Patrizia Presbitero, M.D., director of Interventional Cardiology at Hospital Humanitas Rozzano in Milan and an investigator in the CoreValve ADVANCE Study, and a professional development co-chair and member of the Leadership Council of WIN (Women in Innovations/Society for Cardiovascular Angiography and Interventions, SCAI). "We need to know more about gender differences to effectively treat patients with heart disease in a more specific way, taking into account those differences that can affect treatment."

Women and men benefited similarly from the CoreValve System even though women (51 percent of patients) and men (49 percent of patients) had different risk profiles. Specifically, at the time of enrollment, women as compared to men were:

  • Older than males (82.2 years vs. 79.9 years; p-value <0.001);
  • Had higher average gradients (47.6 vs. 43.5 mmHg; p-value <0.001) and peak gradients (79.0 vs. 72.5 mmHg; p-value <0.001), a measure of blood flow across the valve;
  • Had less coronary artery disease (46 percent vs. 70 percent; p-value <0.001); and
  • Were prescribed fewer cardiovascular medications, including cholesterol-lowering medications (p-value 0.002) and statins (p-value 0.013).

"The robust ADVANCE trial provides a compelling discovery that the CoreValve System is an excellent therapeutic option for both men and women, and it helps us begin to consider how men and women present differently prior to implant and might be managed accordingly," said Axel Linke, M.D., professor of medicine at Universitat Leipzig Herzzentrum in Leipzig, Germany and principal investigator of the ADVANCE clinical trial. "An important next step will be to further evaluate why stroke events were more common for women, including the possible role of medications which were prescribed less frequently for women in this study."    

Source:

Medtronic

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Medtronic. (2019, June 20). Medtronic announces new results from CoreValve ADVANCE Study. News-Medical. Retrieved on May 28, 2022 from https://www.news-medical.net/news/20120518/Medtronic-announces-new-results-from-CoreValve-ADVANCE-Study.aspx.

  • MLA

    Medtronic. "Medtronic announces new results from CoreValve ADVANCE Study". News-Medical. 28 May 2022. <https://www.news-medical.net/news/20120518/Medtronic-announces-new-results-from-CoreValve-ADVANCE-Study.aspx>.

  • Chicago

    Medtronic. "Medtronic announces new results from CoreValve ADVANCE Study". News-Medical. https://www.news-medical.net/news/20120518/Medtronic-announces-new-results-from-CoreValve-ADVANCE-Study.aspx. (accessed May 28, 2022).

  • Harvard

    Medtronic. 2019. Medtronic announces new results from CoreValve ADVANCE Study. News-Medical, viewed 28 May 2022, https://www.news-medical.net/news/20120518/Medtronic-announces-new-results-from-CoreValve-ADVANCE-Study.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Landmark stroke studies presented at ISC, published in NEJM suggest new treatment protocol on the horizon